

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

Whitehawk Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value \$0.0001 per share

(Title of Class of Securities)

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
- ☒ Rule 13d-1(c)
- ☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons
	ABG Management Ltd.
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a) ☐ (b)
3	Sec Use Only
	Citizenship or Place of Organization
4	CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power
	0.00	
		Shared Voting Power
	6	
	817,939.00	
		Sole Dispositive Power
	7	
	0.00	
		Shared Dispositive Power
	8	
	817,939.00	
9	Aggregate Amount Beneficially Owned by Each Reporting Person	
	817,939.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	
	☐	
11	Percent of class represented by amount in row (9)	
	1.4 %	
12	Type of Reporting Person (See Instructions)	
	CO	

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons	
	Ally Bridge Group (NY) LLC	
	Check the appropriate box if a member of a Group (see instructions)	
2	☐	(a)
	☐	(b)
3	Sec Use Only	
4	Citizenship or Place of Organization	
	DELAWARE	
		Sole Voting Power
	5	
	0.00	
Number of Shares Beneficially Owned by Each Reporting Person With:		Shared Voting Power
	6	
	817,939.00	
		Sole Dispositive Power
	7	
	0.00	
		Shared Dispositive Power
	8	
	817,939.00	
9	Aggregate Amount Beneficially Owned by Each Reporting Person	
	817,939.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	
	☐	

11	Percent of class represented by amount in row (9)
	1.4 %
	Type of Reporting Person (See Instructions)
12	OO

SCHEDULE 13G

CUSIP No.

	Names of Reporting Persons
1	Ally Bridge MedAlpha Master Fund L.P.
	Check the appropriate box if a member of a Group (see instructions)

2	☐ (a)
	☐ (b)

3	Sec Use Only
	Citizenship or Place of Organization

4	CAYMAN ISLANDS
---	----------------

	Sole Voting Power
5	0.00
	Shared Voting Power
6	817,939.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive
8	Power

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:

	817,939.00
--	------------

9	Aggregate Amount Beneficially Owned by Each Reporting Person
---	--

	817,939.00
--	------------

10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
----	---

	☐
11	Percent of class represented by amount in row (9)

	1.4 %
	Type of Reporting Person (See Instructions)

12	PN
----	----

SCHEDULE 13G

CUSIP No.

	Names of Reporting Persons
1	ABG Innovation Capital Partners III GP Limited
2	Check the appropriate box if a member of a Group (see instructions)

☐ (a)
☐ (b)

3 Sec Use Only
Citizenship or Place of Organization

4 CAYMAN ISLANDS

Sole Voting Power

5 0.00

Number of Shared Voting Power
Shares

6 0.00

Beneficially Sole Dispositive Power
Owned by

7 0.00

Each Shared Dispositive
Reporting Power
Person

8 0.00

With: 0.00
Aggregate Amount Beneficially Owned by Each Reporting Person

9 0.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10 ☐

Percent of class represented by amount in row (9)

11 0 %

Type of Reporting Person (See Instructions)

12 CO

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1 ABG Innovation Capital Partners III GP, L.P.

Check the appropriate box if a member of a Group (see instructions)

2 ☐ (a)
☐ (b)

3 Sec Use Only
Citizenship or Place of Organization

4 CAYMAN ISLANDS

Sole Voting Power

5 0.00

Number of Shared Voting Power
Shares

6 0.00

Beneficially Sole Dispositive Power
Owned by

7 0.00

Each Shared Dispositive
Reporting Power
Person

8 0.00

With:

	0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	0.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	0 %
12	Type of Reporting Person (See Instructions)
	PN

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons
	Ally Bridge Group Innovation Capital Partners III, L.P.
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	CAYMAN ISLANDS
	Sole Voting Power
5	0.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	0.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive Power
8	0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	0.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	0 %
12	Type of Reporting Person (See Instructions)
	PN

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons
	ABG Innovation-SO Limited
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	VIRGIN ISLANDS, BRITISH
	Sole Voting Power
5	0.00
Number of	Shared Voting Power
Shares	6
Beneficially	0.00
Owned by	Sole Dispositive Power
Each	7
Reporting	0.00
Person	Shared Dispositive
With:	8
	Power
	0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	0.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	0 %
12	Type of Reporting Person (See Instructions)
	CO

SCHEDULE 13G**CUSIP No.**

1	Names of Reporting Persons
	ABG Global Life Science Capital Partners V GP Limited
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	CAYMAN ISLANDS
Number of	Sole Voting Power
Shares	5
Beneficially	0.00
Owned by	6
Each	Shared Voting Power

Reporting Person	4,861,314.00
With:	Sole Dispositive Power
7	0.00
	Shared Dispositive Power
8	4,861,314.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	4,861,314.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	8.1 %
12	Type of Reporting Person (See Instructions)
	CO

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons
	ABG Global Life Science Capital Partners V GP, L.P.
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	CAYMAN ISLANDS
5	Sole Voting Power
	0.00
6	Shared Voting Power
	4,861,314.00
7	Sole Dispositive Power
	0.00
8	Shared Dispositive Power
	4,861,314.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	4,861,314.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	8.1 %
12	Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons
	Ally Bridge Group Global Life Science Capital Partners V, L.P.
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	CAYMAN ISLANDS
	Sole Voting Power
5	0.00
	Shared Voting Power
6	4,861,314.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive
8	Power
	4,861,314.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	4,861,314.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	8.1 %
12	Type of Reporting Person (See Instructions)
	PN

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons
	ABG-SIV, L.P.
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☐ (b)
3	Sec Use Only

4	Citizenship or Place of Organization
	CAYMAN ISLANDS
	Sole Voting Power
5	0.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	4,861,314.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive Power
8	4,861,314.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	4,861,314.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	8.1 %
12	Type of Reporting Person (See Instructions)
	PN

SCHEDULE 13G

CUSIP No.

	Names of Reporting Persons
1	ABG V-SIV Limited
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	CAYMAN ISLANDS
	Sole Voting Power
5	0.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	4,861,314.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive Power
8	4,861,314.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	4,861,314.00

10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	8.1 %
12	Type of Reporting Person (See Instructions)
	CO

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons
	Fan Yu
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	MALTA
	Sole Voting Power
5	0.00
	Shared Voting Power
6	5,679,253.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive
8	Power
	5,679,253.00

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:

9	Aggregate Amount Beneficially Owned by Each Reporting Person
	5,679,253.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	9.4 %
12	Type of Reporting Person (See Instructions)
	IN

SCHEDULE 13G

Item 1.

	Name of issuer:
(a)	Whitehawk Therapeutics, Inc.

(b) Address of issuer's principal executive offices:
2 Headquarters Plaza, East Building, 11th Floor, Morristown, NJ 07960

Item 2.

Name of person filing:

(a) Each of the following is hereinafter individually referred to as a "Reporting Person" and collectively as the "Reporting Persons." This statement is filed on behalf of: ABG Management Ltd. Ally Bridge Group (NY) LLC Ally Bridge MedAlpha Master Fund L.P. ABG Innovation Capital Partners III GP Limited ABG Innovation Capital Partners III GP, L.P. Ally Bridge Group Innovation Capital Partners III, L.P. ABG Innovation-SO Limited ABG Global Life Science Capital Partners V GP Limited ABG Global Life Science Capital Partners V GP, L.P. Ally Bridge Group Global Life Science Capital Partners V, L.P. ABG-SIV, L.P. ABG V-SIV Limited Mr. Fan Yu

Address or principal business office or, if none, residence:

(b) The principal business office address for Ally Bridge Group (NY) LLC is 430 Park Avenue, 12th Floor, New York, NY 10022. The principal business office address for ABG Management Ltd. and Mr. Fan Yu is Unit 3902, 39/F, East Tower Cheung Kong Center II, 10 Harcourt Road Central, Hong Kong. The principal business office address for each of the other Reporting Persons is c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, Grand Cayman, Cayman Islands.

Citizenship:

(c) ABG Innovation-SO Limited is organized under the laws of the British Virgin Islands. Ally Bridge Group (NY) LLC is organized under the laws of the State of Delaware. Mr. Fan Yu is a citizen of Malta. Each of the other Reporting Persons is organized under the laws of the Cayman Islands.

Title of class of securities:

(d) Common Stock, par value \$0.0001 per share

(e) CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

(a) Amount beneficially owned:

The information contained on the cover pages to this Schedule 13G is incorporated by reference into this Item 4. The ownership information presented herein represents beneficial ownership of the Issuer's common stock, par value \$0.0001 per share ("Common Stock"), based on 57,009,010 shares of Common Stock outstanding as of June 30, 2026, as disclosed by the Issuer. The amount of securities reported herein includes: (i) 817,939 shares of Common Stock held of record by Ally Bridge MedAlpha Master Fund LP; (ii) 1,651,388 shares of Common Stock held of record by ABG V-SIV Limited and (iii) 3,209,926 shares of Common Stock issuable upon exercise of warrants held of record by ABG V-SIV Limited. The warrants are currently exercisable and are subject to a 9.99% beneficial ownership limitation on exercise. ABG Innovation SO Limited no longer holds shares in the Issuer. ABG Management Ltd. is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. ABG Global Life Science Capital Partners V GP Limited is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of each of Ally Bridge Group Global Life Science Capital Partners V, L.P. and ABG-SIV, L.P., which are the shareholders of ABG V-SIV Limited. Mr. Fan Yu is the controlling stockholder of each of ABG Management Ltd. and ABG Global Life Science Capital Partners V GP Limited. Accordingly, each of the foregoing entities and Mr. Fan Yu may be deemed to share

beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund LP, ABG and ABG V-SIV Limited. Each of them disclaims beneficial ownership of such securities.

Percent of class:

- (b) See cover pages %
- (c) Number of shares as to which the person has:
- (i) Sole power to vote or to direct the vote:
- See cover pages
- (ii) Shared power to vote or to direct the vote:
- See cover pages
- (iii) Sole power to dispose or to direct the disposition of:
- See cover pages
- (iv) Shared power to dispose or to direct the disposition of:
- See cover pages

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ABG Management Ltd.

Signature: By: /s/ Fan Yu

Name/Title: Fan Yu, Director

Date: 08/14/2026

Ally Bridge Group (NY) LLC

Signature: By: ABG Management Ltd., its managing member, By: /s/ Fan Yu

Name/Title: Fan Yu, Director

Date: 08/14/2026

Ally Bridge MedAlpha Master Fund L.P.

Signature: By: Ally Bridge Group (NY) LLC, its manager, By: ABG Management Ltd., its managing member, By: /s/ Fan Yu

Name/Title: Fan Yu, Director

Date: 08/14/2026

ABG Innovation Capital Partners III GP Limited

Signature: By: /s/ Fan Yu
Name/Title: Fan Yu, Director
Date: 08/14/2026

ABG Innovation Capital Partners III GP, L.P.

Signature: By: ABG Innovation Capital Partners III GP Limited, its general partner, By: /s/ Fan Yu
Name/Title: Fan Yu, Director
Date: 08/14/2026

Ally Bridge Group Innovation Capital Partners III, L.P.

Signature: By: ABG Innovation Capital Partners III GP, L.P.,
By: ABG Innovation Capital Partners III GP Limited, By: /s/ Fan Yu
Name/Title: Fan Yu, Director
Date: 08/14/2026

ABG Innovation-SO Limited

Signature: By: /s/ Shan-ju Yeh
Name/Title: Shan-ju Yeh, Director
Date: 08/14/2026

ABG Global Life Science Capital Partners V GP Limited

Signature: By: /s/ Shan-ju Yeh
Name/Title: Shan-ju Yeh, Director
Date: 08/14/2026

ABG Global Life Science Capital Partners V GP, L.P.

Signature: By: ABG Global Life Science Capital Partners V GP Limited, its general partner, By: /s/ Shan-ju Yeh
Name/Title: Shan-ju Yeh, Director
Date: 08/14/2026

Ally Bridge Group Global Life Science Capital Partners V, L.P.

Signature: By: ABG Global Life Science Capital Partners V GP, L.P., ABG Global Life Science Capital Partners V GP Limited, /s/ Shan-ju Yeh
Name/Title: Shan-ju Yeh, Director
Date: 08/14/2026

ABG-SIV, L.P.

Signature: By: ABG Global Life Science Capital Partners V GP, L.P., ABG Global Life Science Capital Partners V GP Limited, /s/ Shan-ju Yeh
Name/Title: Shan-ju Yeh, Director
Date: 08/14/2026

ABG V-SIV Limited

Signature: By: /s/ Shan-ju Yeh
Name/Title: Shan-ju Yeh, Director
Date: 08/14/2026

Fan Yu

Signature: /s/ Fan Yu
Name/Title: Fan Yu

Date: 08/14/2026

Exhibit Information

Exhibit 99: Joint Filing Agreement (previously filed).